AAPL341.44+1.36 (+0.40%) ▲|ABBV266.37+3.17 (+1.20%) ▲|ABT109.40+2.13 (+1.98%) ▲|ACN174.59+9.93 (+6.03%) ▲|ADBE262.96+13.78 (+5.53%) ▲|AMAT445.82-30.64 (-6.43%) ▼|AMD429.30-25.32 (-5.57%) ▼|AMGN390.22-2.89 (-0.73%) ▼|AMT172.85+1.35 (+0.79%) ▲|AMZN229.02-1.84 (-0.80%) ▼|AVGO373.31-7.60 (-2.00%) ▼|AXP333.69-2.94 (-0.87%) ▼|BA211.13-10.43 (-4.71%) ▼|BAC61.70-0.92 (-1.47%) ▼|BKNG201.24+1.93 (+0.97%) ▲|BLK1,099.86+2.31 (+0.21%) ▲|BMY63.56-0.05 (-0.07%) ▼|BNY154.06-2.43 (-1.55%) ▼|BRK-B509.85-2.53 (-0.49%) ▼|C128.26-4.21 (-3.18%) ▼|CAT782.07-58.79 (-6.99%) ▼|CL92.82+0.09 (+0.10%) ▲|CMCSA24.63+0.44 (+1.80%) ▲|COF210.73-1.68 (-0.79%) ▼|COP118.14+4.04 (+3.54%) ▲|COST976.79+10.21 (+1.06%) ▲|CRM188.52+7.02 (+3.87%) ▲|CSCO114.96-0.62 (-0.54%) ▼|CVS107.31-2.03 (-1.86%) ▼|CVX192.27+4.69 (+2.50%) ▲|DE613.53-26.31 (-4.11%) ▼|DHR199.74+0.69 (+0.35%) ▲|DIS98.65-0.24 (-0.24%) ▼|DUK129.61+0.37 (+0.29%) ▲|EMR145.75-6.06 (-3.99%) ▼|FDX309.11-3.53 (-1.13%) ▼|GD388.55-4.65 (-1.18%) ▼|GE351.10-12.50 (-3.44%) ▼|GEV905.44-37.95 (-4.02%) ▼|GILD133.75-0.58 (-0.43%) ▼|GM89.81-0.49 (-0.54%) ▼|GOOG334.48+1.88 (+0.57%) ▲|GOOGL335.38+1.67 (+0.50%) ▲|GS988.61-44.73 (-4.33%) ▼|HD341.39-3.08 (-0.89%) ▼|HON241.43-5.63 (-2.28%) ▼|IBM227.53-0.02 (-0.01%) ▼|INTC83.31-2.99 (-3.46%) ▼|INTU332.80+19.81 (+6.33%) ▲|ISRG355.28-6.53 (-1.80%) ▼|JNJ267.25+0.52 (+0.20%) ▲|JPM348.09-9.23 (-2.58%) ▼|KO89.91+1.64 (+1.86%) ▲|LIN507.53-3.65 (-0.71%) ▼|LLY1,217.51-3.16 (-0.26%) ▼|LMT572.52-8.79 (-1.51%) ▼|LOW216.84-1.40 (-0.64%) ▼|LRCX253.96-15.65 (-5.80%) ▼|MA568.20+5.45 (+0.97%) ▲|MCD271.95-1.07 (-0.39%) ▼|MDLZ65.30+2.82 (+4.51%) ▲|MDT88.20+1.32 (+1.51%) ▲|META590.56-2.86 (-0.48%) ▼|MMM179.56-2.92 (-1.60%) ▼|MO75.26+0.44 (+0.59%) ▲|MRK131.41-0.41 (-0.31%) ▼|MS204.46-7.13 (-3.37%) ▼|MSFT395.45+2.10 (+0.53%) ▲|MU775.13-45.41 (-5.53%) ▼|NEE89.04-0.25 (-0.27%) ▼|NFLX73.10+0.71 (+0.97%) ▲|NKE42.61-0.45 (-1.03%) ▼|NOW116.04+5.42 (+4.90%) ▲|NVDA191.53-5.49 (-2.78%) ▼|ORCL117.23-2.73 (-2.28%) ▼|PEP144.69+1.83 (+1.28%) ▲|PFE25.26+0.01 (+0.06%) ▲|PG145.13-3.75 (-2.52%) ▼|PLTR124.95+1.42 (+1.15%) ▲|PM199.69-0.48 (-0.24%) ▼|QCOM159.78-3.10 (-1.90%) ▼|RTX216.11-2.47 (-1.13%) ▼|SBUX104.11+1.01 (+0.97%) ▲|SCHW106.44+0.47 (+0.44%) ▲|SO96.61-0.18 (-0.18%) ▼|SPG237.02+0.32 (+0.13%) ▲|T24.43-0.24 (-0.95%) ▼|TMO576.09-0.32 (-0.06%) ▼|TMUS181.16-1.23 (-0.67%) ▼|TSLA300.99-6.45 (-2.10%) ▼|TXN269.88-7.19 (-2.60%) ▼|UBER70.50-0.24 (-0.34%) ▼|UNH424.70-4.09 (-0.95%) ▼|UNP291.95-2.50 (-0.85%) ▼|UPS105.04-0.49 (-0.46%) ▼|USB63.56-0.88 (-1.36%) ▼|V373.42+6.83 (+1.86%) ▲|VZ48.09-0.11 (-0.22%) ▼|WFC84.99-1.89 (-2.17%) ▼|WMT113.93+0.83 (+0.73%) ▲|XOM157.17+4.13 (+2.70%) ▲|AAPL341.44+1.36 (+0.40%) ▲|ABBV266.37+3.17 (+1.20%) ▲|ABT109.40+2.13 (+1.98%) ▲|ACN174.59+9.93 (+6.03%) ▲|ADBE262.96+13.78 (+5.53%) ▲|AMAT445.82-30.64 (-6.43%) ▼|AMD429.30-25.32 (-5.57%) ▼|AMGN390.22-2.89 (-0.73%) ▼|AMT172.85+1.35 (+0.79%) ▲|AMZN229.02-1.84 (-0.80%) ▼|AVGO373.31-7.60 (-2.00%) ▼|AXP333.69-2.94 (-0.87%) ▼|BA211.13-10.43 (-4.71%) ▼|BAC61.70-0.92 (-1.47%) ▼|BKNG201.24+1.93 (+0.97%) ▲|BLK1,099.86+2.31 (+0.21%) ▲|BMY63.56-0.05 (-0.07%) ▼|BNY154.06-2.43 (-1.55%) ▼|BRK-B509.85-2.53 (-0.49%) ▼|C128.26-4.21 (-3.18%) ▼|CAT782.07-58.79 (-6.99%) ▼|CL92.82+0.09 (+0.10%) ▲|CMCSA24.63+0.44 (+1.80%) ▲|COF210.73-1.68 (-0.79%) ▼|COP118.14+4.04 (+3.54%) ▲|COST976.79+10.21 (+1.06%) ▲|CRM188.52+7.02 (+3.87%) ▲|CSCO114.96-0.62 (-0.54%) ▼|CVS107.31-2.03 (-1.86%) ▼|CVX192.27+4.69 (+2.50%) ▲|DE613.53-26.31 (-4.11%) ▼|DHR199.74+0.69 (+0.35%) ▲|DIS98.65-0.24 (-0.24%) ▼|DUK129.61+0.37 (+0.29%) ▲|EMR145.75-6.06 (-3.99%) ▼|FDX309.11-3.53 (-1.13%) ▼|GD388.55-4.65 (-1.18%) ▼|GE351.10-12.50 (-3.44%) ▼|GEV905.44-37.95 (-4.02%) ▼|GILD133.75-0.58 (-0.43%) ▼|GM89.81-0.49 (-0.54%) ▼|GOOG334.48+1.88 (+0.57%) ▲|GOOGL335.38+1.67 (+0.50%) ▲|GS988.61-44.73 (-4.33%) ▼|HD341.39-3.08 (-0.89%) ▼|HON241.43-5.63 (-2.28%) ▼|IBM227.53-0.02 (-0.01%) ▼|INTC83.31-2.99 (-3.46%) ▼|INTU332.80+19.81 (+6.33%) ▲|ISRG355.28-6.53 (-1.80%) ▼|JNJ267.25+0.52 (+0.20%) ▲|JPM348.09-9.23 (-2.58%) ▼|KO89.91+1.64 (+1.86%) ▲|LIN507.53-3.65 (-0.71%) ▼|LLY1,217.51-3.16 (-0.26%) ▼|LMT572.52-8.79 (-1.51%) ▼|LOW216.84-1.40 (-0.64%) ▼|LRCX253.96-15.65 (-5.80%) ▼|MA568.20+5.45 (+0.97%) ▲|MCD271.95-1.07 (-0.39%) ▼|MDLZ65.30+2.82 (+4.51%) ▲|MDT88.20+1.32 (+1.51%) ▲|META590.56-2.86 (-0.48%) ▼|MMM179.56-2.92 (-1.60%) ▼|MO75.26+0.44 (+0.59%) ▲|MRK131.41-0.41 (-0.31%) ▼|MS204.46-7.13 (-3.37%) ▼|MSFT395.45+2.10 (+0.53%) ▲|MU775.13-45.41 (-5.53%) ▼|NEE89.04-0.25 (-0.27%) ▼|NFLX73.10+0.71 (+0.97%) ▲|NKE42.61-0.45 (-1.03%) ▼|NOW116.04+5.42 (+4.90%) ▲|NVDA191.53-5.49 (-2.78%) ▼|ORCL117.23-2.73 (-2.28%) ▼|PEP144.69+1.83 (+1.28%) ▲|PFE25.26+0.01 (+0.06%) ▲|PG145.13-3.75 (-2.52%) ▼|PLTR124.95+1.42 (+1.15%) ▲|PM199.69-0.48 (-0.24%) ▼|QCOM159.78-3.10 (-1.90%) ▼|RTX216.11-2.47 (-1.13%) ▼|SBUX104.11+1.01 (+0.97%) ▲|SCHW106.44+0.47 (+0.44%) ▲|SO96.61-0.18 (-0.18%) ▼|SPG237.02+0.32 (+0.13%) ▲|T24.43-0.24 (-0.95%) ▼|TMO576.09-0.32 (-0.06%) ▼|TMUS181.16-1.23 (-0.67%) ▼|TSLA300.99-6.45 (-2.10%) ▼|TXN269.88-7.19 (-2.60%) ▼|UBER70.50-0.24 (-0.34%) ▼|UNH424.70-4.09 (-0.95%) ▼|UNP291.95-2.50 (-0.85%) ▼|UPS105.04-0.49 (-0.46%) ▼|USB63.56-0.88 (-1.36%) ▼|V373.42+6.83 (+1.86%) ▲|VZ48.09-0.11 (-0.22%) ▼|WFC84.99-1.89 (-2.17%) ▼|WMT113.93+0.83 (+0.73%) ▲|XOM157.17+4.13 (+2.70%) ▲|
26.8 C
New York
Wednesday, July 29, 2026

Tag: error

newssourceFORcompanyinformationcontent1releasesmarket

FDA Approves TYLENOL® with Naproxen, the First and Only Over-the-Counter Fixed-Dose Combination of Acetaminophen (650 mg) and Naproxen Sodium (220 mg)

TYLENOL® with Naproxen is a clinically proven, opioid-free, fixed-dose combination that begins working in under 30 minutes and provides 12 hours of pain relief...

Next Stop, Scotland?

Going home isn't so bad when it looks like this...BOSTON, June 29, 2026 /PRNewswire/ -- While others are planning their route to the final,...

Johnson & Johnson presents new IMAAVY®▼ (nipocalimab) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalised myasthenia gravis

BEERSE, BELGIUM, June 26, 2026 (GLOBE NEWSWIRE) -- Johnson & Johnson today announced new data across 12 abstracts at the European Academy of Neurology (EAN) 2026 Congress that offer additional insight into the use of IMAAVY®▼(nipocalimab) throughout clinically relevant points in the generalised myasthenia gravis (gMG) treatment journey. The analyses include adults with anti-AChRa or anti-MuSKb antibody-positive gMG who were early in their disease course or had lower baseline symptom burden – providing insight into the potential importance of addressing pathogenic immunoglobulin G (IgG) early in disease progression where use of advanced therapies may be less common.1,2 Additional research to be shared include outcomes shortly after common infections, which are a known cause of disease exacerbations in gMG, and plans to address evidence gaps in the use of nipocalimab during pregnancy.3,4

Johnson & Johnson presents new IMAAVY® (nipocalimab-aahu) data at European Academy of Neurology (EAN) 2026 Congress reinforcing sustained disease control in generalized myasthenia gravis

New analyses from the Phase 3 Vivacity-MG3 study support the impact of IMAAVY in anti-AChR+a, anti-MuSK+b adult patients with generalized myasthenia gravis (gMG) including...

Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference

SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for rare diseases, today announced positive five-year data from its ongoing HOPE-2 Open-Label Extension (OLE) study of Deramiocel, the Company’s lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD). The data will be presented at the Parent Project Muscular Dystrophy (PPMD) 2026 Annual Conference, taking place June 25-27, 2026, in Orlando, Florida, alongside previously reported results from the Company’s HOPE-3 Phase 3 trial.

E Fund (HK) HKEX Tech 100 Index ETF (3456) Lists Today

First ETF Tracking the HKEX Tech 100 Index – One-Click Access to Six Key Tech Innovation ThemesHONG KONG, June 26, 2026 /PRNewswire/ -- E Fund...

Silvercorp Announces Filing of Updated Technical Reports

Trading Symbol: TSX/NYSE American: SVMVANCOUVER, BC, June 24, 2026 /PRNewswire/ - Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE American: SVM) announces...

Silvercorp Announces Filing of Updated Technical Reports

Trading Symbol: TSX/NYSE American: SVMVANCOUVER, BC, June 24, 2026 /CNW/ - Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE American: SVM) announces...

Commvault Signs Multi-Year Strategic Partnership with Microsoft

 As more organizations deploy AI and face cyber threats, Commvault's AI and cyber resilience platform will be integrated and delivered as a native ISV...

RoenRx Releases 2026 Weight-Loss Program Pricing and Treatment Cost Overview

New York, NY, June 23, 2026 (GLOBE NEWSWIRE) -- RoenRx, a telehealth platform providing medically supervised weight-loss care, today released updated 2026 pricing information for its weight-loss program, detailing membership costs, insurance-supported GLP-1 treatment options, compounded medication pricing, bundled care plans, and subscription terms. The pricing overview is intended to provide prospective patients with greater transparency regarding the potential costs associated with RoenRx's weight-management services and available treatment pathways.

/UPDATE — Owl AI, Inc./

UPDATE - This release has been updated to include a photo of the new CEO provided by OWL AI OWL AI Names Jay Prasad Chief...

Delta Thailand Highlights Integrated Smart and Green Manufacturing Solutions for Intelligent Factory Operations at Manufacturing Expo 2026

BANGKOK, June 18, 2026 /PRNewswire/ -- Delta Electronics (Thailand) Public Company Limited, a global leader in power management and smart green solutions, is showcasing its...

SandboxAQ Signs Definitive Agreement with the U.S. Department of Commerce for $500 Million CHIPS R&D Award

SandboxAQ will use physics-based AI to develop, validate, and then commercialize critical formulations for American semiconductor manufacturing and to drive national security needsPALO ALTO,...

The Quiet Bottleneck in AI Drug Discovery Isn’t the Model — It’s the Biology Underneath It

Issued on behalf of MindWalk Holdings Corp.Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsError

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers